One analyst is now more bullish about this clinical-stage biotech stock. Shares of Nkarta (NKTX 1.61%) were soaring 11.1% as of 11:07 a.m. ET on Wednesday. The big gain came after Raymond James upgraded the stock from outperform to a strong buy and maintained its 12-month price target at $16. This analyst upgrade came after Nkarta provided its second-quarter update on Tuesday. The clinical-stage biopharmaceutical company expects to begin patient enrollment by year-end in an Ntrust-2 clinical trial evaluatin ...